PRESS RELEASE: EORTC and CDDF announce new collaboration
18 Jun 2020
CDDF provides a neutral platform to stimulate interactions between all stakeholders involved in cancer drug development. The aim of the organization is to accelerate the delivery of effective oncology agents to patients by encouraging multi-stakeholder discussions.
The collaboration will foster dialogue on common issues in clinical cancer research especially with other stakeholders. Both organisations intend to organise joint workshops and offer support and endorsement in each other’s events.
“Through the partnership with EORTC, one of the most important academic clinical research organizations worldwide, we believe we are offering unique value to stimulate advancement in oncology treatment and delivery” said Professor Jaap Verweij, CDDF Managing Director. “We believe collaboration is the key to improving outcomes for cancer patients and we look forward to a strong alliance with EORTC that will help identify and overcome challenges in the development and delivery of cancer drugs and deliver swift benefits to cancer patients.”
“This is an important partnership for EORTC,” said Dr Denis Lacombe, EORTC Director General. “CDDF has been instrumental in discussions with regulators and other stakeholders and with our combined efforts, we can bring challenging issues to the wider oncology community producing effective outcomes.”
About EORTC
EORTC, an academic clinical research organization, bringing together European clinical investigators from all disciplines across all tumour types to conduct research that improves quality of life and survival of cancer patients. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life. EORTC network comprises more than 5300 professionals in over 1000 hospitals and institutes in more than 30 countries supported by 230 staff in its Headquarters in Brussels.
About CDDF
The Cancer Drug Development Forum (CDDF) is a leading non-competitive drug development platform in Europe whose sole objective is to stimulate advancement in cancer drug development and access.
CDDF integrative approach aims to bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to accelerate effective drug development in oncology treatment and shorten time to market, and time to patient access.
For more information on Cancer Drug Development Forum, please visit www.cddf.org
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023